课题基金 / 基金详情

Incretin-based Drugs and the Risk of Adverse Renal Outcomes

Incretin-based Drugs and the Risk of Adverse Renal Outcomes
基于肠促胰岛素的药物和不良肾脏后果的风险
批准号：
351868
负责人：
Filion Kristian B
金额：
$7.29万
依托单位：
Lady Davis Institute for Medical Research (Mtl)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2016
资助国家：
加拿大
项目状态：
已结题
起止时间：
2016-04-01 至 2017-04-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=351868&lang=en
关键词：
Acute Kidney Injury Database Dpp-4 Inhibitors Drug Safety Epidemiology Glp-1 Analogs Incretin-Based Drugs Kidneys Pharmacoepidemiology Type 2 Diabetes

项目摘要

项目成果

Filion Kristian B的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Incretin-based drugs are used to treat type 2 diabetes. While they have several benefits, their safety is controversial. Current evidence regarding their effects on the kidneys is conflicting. The results of some clinical trials suggest that these drugs
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Comparative Effectiveness of Long-acting Insulins and Neutral Protamine Hagedorn (NPH) Insulin for the Prevention of Micro- and Macrovascular Complications Among Patients with Type 1 Diabetes
The Safety of Antipsychotic Drugs Among Children and Youth With Attention Deficit and Hyperactivity Disorder
Comparative Effectiveness and Safety of Long-acting Insulins and Neutral Protamine Hagedorn (NPH) Insulin among Patients with Type 2 Diabetes
A population-based assessment of pharmacological treatments for gestational diabetes
海外基金